

Celsion Corporation Investor Relations Department 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: CLSN Last Trade: 2.28 Trade Time: 9:31 AM ET Jun 27, 2017 Change: -0.09 ♣ (-3.797%) Day Range 2.27 - 2.39 52-Week Range 2.03 - 19.61 Volume 17,835

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the sideeffects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heatsensitive liposomal nanoparticle licensed from Duke Universit... (more)

Stock Performance



Press Releases [View all]

Jun 22, 2017

<u>Celsion Corporation Announces Cancellation</u> of Registered Direct Offering

Jun 19, 2017

Celsion Corporation Announces \$5.4 Million Registered Direct Offering

Jun 14, 2017

<u>Celsion Corporation Regains Compliance with</u>
NASDAQ Listing Requirements

Jun 5, 2017

Celsion Announces Presentation of
OVATION Study Findings at the ASCO 2017
Annual Meeting

May 26, 2017

<u>Celsion Corporation Announces Stock</u> Consolidation

Financials [View all]

First Quarter Financial Results

Mar 24, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

May 12, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)

Aug 15, 2016

Quarterly Report (10-Q)